WO2008118141A3 - Utilisation de composés de modulation des cannabinoïdes en association avec d'autres composés thérapeutiques comme traitement d'appoint - Google Patents

Utilisation de composés de modulation des cannabinoïdes en association avec d'autres composés thérapeutiques comme traitement d'appoint Download PDF

Info

Publication number
WO2008118141A3
WO2008118141A3 PCT/US2007/022464 US2007022464W WO2008118141A3 WO 2008118141 A3 WO2008118141 A3 WO 2008118141A3 US 2007022464 W US2007022464 W US 2007022464W WO 2008118141 A3 WO2008118141 A3 WO 2008118141A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
combination
adjunctive therapy
cannabinoid
therapeutic
Prior art date
Application number
PCT/US2007/022464
Other languages
English (en)
Other versions
WO2008118141A2 (fr
Inventor
Ethan S Burstein
Luis R Gardell
Original Assignee
Acadia Pharm Inc
Ethan S Burstein
Luis R Gardell
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acadia Pharm Inc, Ethan S Burstein, Luis R Gardell filed Critical Acadia Pharm Inc
Publication of WO2008118141A2 publication Critical patent/WO2008118141A2/fr
Publication of WO2008118141A3 publication Critical patent/WO2008118141A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des compositions pharmaceutiques qui contiennent un composé qui module l'activité d'un récepteur cannabinoïde conjointement avec un autre composé thérapeutique et des utilisations des composés qui modulent l'activité d'un récepteur cannabinoïde conjointement avec un autre composé thérapeutique pour traiter diverses affections (par exemple les effets secondaires).
PCT/US2007/022464 2006-10-17 2007-10-17 Utilisation de composés de modulation des cannabinoïdes en association avec d'autres composés thérapeutiques comme traitement d'appoint WO2008118141A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85262206P 2006-10-17 2006-10-17
US60/852,622 2006-10-17

Publications (2)

Publication Number Publication Date
WO2008118141A2 WO2008118141A2 (fr) 2008-10-02
WO2008118141A3 true WO2008118141A3 (fr) 2008-12-24

Family

ID=39731088

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/022464 WO2008118141A2 (fr) 2006-10-17 2007-10-17 Utilisation de composés de modulation des cannabinoïdes en association avec d'autres composés thérapeutiques comme traitement d'appoint

Country Status (1)

Country Link
WO (1) WO2008118141A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9115096B2 (en) 2011-05-10 2015-08-25 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators
US9193694B2 (en) 2011-07-01 2015-11-24 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators
US9371329B2 (en) 2009-07-27 2016-06-21 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009035997A2 (fr) 2007-09-14 2009-03-19 Cara Therapeutics, Inc. Hétérocycles benzo-fusionnés
JP2011162472A (ja) * 2010-02-09 2011-08-25 Nippon Soda Co Ltd 含窒素ヘテロ環化合物またはその塩、ならびに農園芸用殺菌剤
BR112012033402A2 (pt) 2010-07-02 2017-01-24 Gilead Sciences Inc moduladores de canais de íons conforme os compostos heterocíclicos fundidos
CN102807574B (zh) * 2011-05-30 2015-09-02 长春吉大天元化学技术股份有限公司 新型吡啶并硫氮七元环衍生物作为抗肿瘤药物、及其制备方法和应用
NO3175985T3 (fr) 2011-07-01 2018-04-28
US20130337052A1 (en) * 2012-06-19 2013-12-19 Patricia Linert System and Method of Reducing Impairment of Alertness, Concentration, Motivation, and Creativity Caused by Medication
PT3116316T (pt) 2014-03-13 2019-09-30 Assembly Biosciences Inc Moduladores alostéricos da proteína do núcleo da hepatite b
TW201720802A (zh) 2015-09-15 2017-06-16 艾森伯利生物科學公司 B型肝炎核心蛋白質調節劑
CN109937201A (zh) 2016-09-15 2019-06-25 组装生物科学股份有限公司 乙型肝炎核心蛋白调节剂
CA3077624A1 (fr) 2016-10-01 2018-04-05 James Smeeding Compositions pharmaceutiques comprenant une statine et un cannabinoide et leurs utilisations
US20180147141A1 (en) * 2016-11-29 2018-05-31 Axim Biotechnologies, Inc. Chewing gum composition comprising cannabinoids and gabapentin
EP3589630B1 (fr) 2017-03-02 2021-07-07 Assembly Biosciences, Inc. Composés de sulfamide cyclique et leurs procédés d'utilisation
AU2018236188B2 (en) 2017-03-13 2022-01-27 Assembly Biosciences, Inc. Process for making hepatitis B core protein modulators
CN114929688A (zh) 2019-10-21 2022-08-19 阿莱瑞恩公司 作为H1和5-HT2A-受体调节剂、用于治疗睡眠障碍的3-(4-(11H-二苯并[b,e][1,4]吖庚英-6-基)哌嗪-1-基)-和3-(4-(二苯并[b,f][1,4]氧杂吖庚英/硫杂吖庚英/二吖庚英-11-基)哌嗪-1-基)-丙酸衍生物
WO2024104818A1 (fr) 2022-11-16 2024-05-23 Basf Se Benzodiazépines substituées utilisées comme fongicides
WO2024104822A1 (fr) 2022-11-16 2024-05-23 Basf Se Tétrahydrobenzodiazépines substituées utilisées comme fongicides
WO2024104815A1 (fr) 2022-11-16 2024-05-23 Basf Se Benzodiazépines substituées utilisées comme fongicides

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002049652A1 (fr) * 2000-12-20 2002-06-27 Astrazeneca Ab Procede de traitement
WO2004073639A2 (fr) * 2003-02-19 2004-09-02 Merck & Co. Inc. Traitement de la psychose avec un activateur ectopique du recepteur m1 muscarinique
WO2005000809A1 (fr) * 2003-06-11 2005-01-06 Merck & Co., Inc. Derives 3-alkyle et 3-alcenyle azetidine substitues
WO2005002586A1 (fr) * 2003-07-02 2005-01-13 Astrazeneca Ab Metabolite de quetiapine
WO2005023243A1 (fr) * 2003-09-04 2005-03-17 H. Lundbeck A/S Combinaison d'un inhibiteur de recaptage de serotonine et de loxapine
US20050096311A1 (en) * 2003-10-30 2005-05-05 Cns Response Compositions and methods for treatment of nervous system disorders
WO2005063254A2 (fr) * 2003-12-22 2005-07-14 Acadia Pharmaceuticals Inc. Analogues de diaryl[a,d]cycloheptene amino substitues utilises comme agonistes muscariniques, et procedes de traitement de troubles neuropsychiatriques
WO2005070461A2 (fr) * 2004-01-13 2005-08-04 Duke University Compositions anticonvulsives, medicament antipsychotique et leurs methodes d'utilisation permettant d'influer sur la perte de poids
WO2005115977A1 (fr) * 2004-05-28 2005-12-08 Tanabe Seiyaku Co., Ltd. Dérivés de pyrrolidine servant d'antagonistes du récepteur cb1
WO2006107948A2 (fr) * 2005-04-04 2006-10-12 Acadia Pharmaceuticals Inc. Utilisation de n-desmethylclozapine et de composes associes comme agents stabilisateurs de dopamine
WO2007018460A1 (fr) * 2005-08-08 2007-02-15 Astrazeneca Ab Agents thérapeutiques
WO2007047737A1 (fr) * 2005-10-17 2007-04-26 Acadia Pharmaceuticals Inc. Composes modulateurs de cb-1 et leur utilisation

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002049652A1 (fr) * 2000-12-20 2002-06-27 Astrazeneca Ab Procede de traitement
WO2004073639A2 (fr) * 2003-02-19 2004-09-02 Merck & Co. Inc. Traitement de la psychose avec un activateur ectopique du recepteur m1 muscarinique
WO2005000809A1 (fr) * 2003-06-11 2005-01-06 Merck & Co., Inc. Derives 3-alkyle et 3-alcenyle azetidine substitues
WO2005002586A1 (fr) * 2003-07-02 2005-01-13 Astrazeneca Ab Metabolite de quetiapine
WO2005023243A1 (fr) * 2003-09-04 2005-03-17 H. Lundbeck A/S Combinaison d'un inhibiteur de recaptage de serotonine et de loxapine
US20050096311A1 (en) * 2003-10-30 2005-05-05 Cns Response Compositions and methods for treatment of nervous system disorders
WO2005063254A2 (fr) * 2003-12-22 2005-07-14 Acadia Pharmaceuticals Inc. Analogues de diaryl[a,d]cycloheptene amino substitues utilises comme agonistes muscariniques, et procedes de traitement de troubles neuropsychiatriques
WO2005070461A2 (fr) * 2004-01-13 2005-08-04 Duke University Compositions anticonvulsives, medicament antipsychotique et leurs methodes d'utilisation permettant d'influer sur la perte de poids
WO2005115977A1 (fr) * 2004-05-28 2005-12-08 Tanabe Seiyaku Co., Ltd. Dérivés de pyrrolidine servant d'antagonistes du récepteur cb1
WO2006107948A2 (fr) * 2005-04-04 2006-10-12 Acadia Pharmaceuticals Inc. Utilisation de n-desmethylclozapine et de composes associes comme agents stabilisateurs de dopamine
WO2007018460A1 (fr) * 2005-08-08 2007-02-15 Astrazeneca Ab Agents thérapeutiques
WO2007047737A1 (fr) * 2005-10-17 2007-04-26 Acadia Pharmaceuticals Inc. Composes modulateurs de cb-1 et leur utilisation

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ANDERSON JEFFREY J ET AL: "Effects of cannabinoid receptor stimulation and blockade on catalepsy produced by dopamine receptor antagonists", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 295, no. 2-3, 1996, pages 163 - 168, XP002495957, ISSN: 0014-2999 *
MUCCIOLI G G ET AL: "Current knowledge on the antagonists and inverse agonists of cannabinoid receptors", CURRENT MEDICINAL CHEMISTRY, BENTHAM SCIENCE PUBLISHERS BV, BE, vol. 12, no. 12, 1 January 2005 (2005-01-01), pages 1361 - 1394, XP008082642, ISSN: 0929-8673 *
ROGERS-EVANS M ET AL: "Identification of novel cannabinoid receptor ligands via evolutionary de novo design and rapid parallel synthesis", QSAR AND COMBINATORIAL SCIENCE 200407 DE, vol. 23, no. 6, July 2004 (2004-07-01), pages 426 - 430, XP002495955, ISSN: 1611-020X *
SEGOVIA GREGORIO ET AL: "Effects of CB1 cannabinoid receptor modulating compounds on the hyperkinesia induced by high-dose levodopa in the reserpine-treated rat model of Parkinson's disease.", MOVEMENT DISORDERS : OFFICIAL JOURNAL OF THE MOVEMENT DISORDER SOCIETY FEB 2003, vol. 18, no. 2, February 2003 (2003-02-01), pages 138 - 149, XP002495956, ISSN: 0885-3185 *
SUNDRAM S ET AL: "Clozapine decreases [3H] CP 55940 binding to the cannabinoid1 receptor in the rat accumbens", NAUNYN-SCHMIEDEBERG'S ARCHIVES OF PHARMACOLOGY, SPRINGER, BERLIN, DE, vol. 371, 2 July 2005 (2005-07-02), pages 428 - 433, XP002420595, ISSN: 0028-1298 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9371329B2 (en) 2009-07-27 2016-06-21 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators
US9115096B2 (en) 2011-05-10 2015-08-25 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators
US9403782B2 (en) 2011-05-10 2016-08-02 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators
US9193694B2 (en) 2011-07-01 2015-11-24 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators

Also Published As

Publication number Publication date
WO2008118141A2 (fr) 2008-10-02

Similar Documents

Publication Publication Date Title
WO2008118141A3 (fr) Utilisation de composés de modulation des cannabinoïdes en association avec d'autres composés thérapeutiques comme traitement d'appoint
WO2007092190A3 (fr) Procedes et compositions permettant de moduler l'activite du recepteur du sphingosine-1-phosphate (s1p)
WO2007109330A3 (fr) Composés modulant le récepteur de la sip
WO2007092065A3 (fr) Composés et compositions servant de modulateurs du lxr
WO2006012642A3 (fr) Derives de pyrrole en tant qu'agents pharmaceutiques
TW200745124A (en) Azepinoindole derivatives as pharmaceutical agents
TW200801021A (en) Imidazolothiazole compounds for the treatment of disease
ECSP067043A (es) Derivados de pirrolotriazina útiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogénesis
WO2009076454A3 (fr) Compositions qui modulant le calcium intracellulaire
WO2006125539A3 (fr) Therapie de combinaisons comprenant des urees diaryle destinee a traiter des maladies
WO2008070268A3 (fr) Compositions pharmaceutiques
IL195030A (en) IV dpp inhibitor assemblies
BRPI0509207A (pt) moduladores canabinóides de tetraidro-indazol
WO2007024717A3 (fr) Agents permettant de prevenir et de traiter des troubles entrainant la modulation des recepteurs ryr
TN2010000122A1 (en) Compounds and compositions as modulators of gpr119 activity
WO2005016286A8 (fr) Modulateurs pyraziniques de recepteurs canabinoïdes
AU2008232453A8 (en) Methods and compositions for reduction of side effects of therapeutic treatments
MX2009009491A (es) Compuestos y composiciones como moduladores de la actividad del gpr119.
WO2009035818A8 (fr) Composés modulant le calcium intracellulaire
WO2010118063A3 (fr) Compositions thérapeutiques et procédés d'utilisation associés
WO2008076754A3 (fr) Composés et compositions utilisés comme inhibiteurs de l'activité du récepteur cannabinoïde 1
PL1979355T3 (pl) Pochodne spiro imidazoli jako modulatory PPAR
TNSN08373A1 (en) Azolopyrimidines as inhibitors of cannabinoid 1 activity
TW200740429A (en) Methods and dosage forms for reducing side effects of carbamate compounds
WO2005077122A3 (fr) Composes et compositions convenant comme modulateurs des lxr

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07873455

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07873455

Country of ref document: EP

Kind code of ref document: A2